D.A. Davidson & Co. Argenx Se Transaction History
D.A. Davidson & Co.
- $13.8 Billion
- Q2 2025
A detailed history of D.A. Davidson & Co. transactions in Argenx Se stock. As of the latest transaction made, D.A. Davidson & Co. holds 1,196 shares of ARGX stock, worth $955,532. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,196Holding current value
$955,532% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ARGX
# of Institutions
492Shares Held
28.2MCall Options Held
370KPut Options Held
211K-
Price T Rowe Associates Inc Baltimore, MD4.98MShares$3.98 Billion0.31% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.79MShares$2.23 Billion2.84% of portfolio
-
Janus Henderson Group PLC London, X02.57MShares$2.05 Billion0.73% of portfolio
-
Capital World Investors Los Angeles, CA1.95MShares$1.56 Billion0.16% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.18MShares$939 Million11.81% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $44.2B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...